| JPM THEMATICS-GENETIC THERAPIES C (DIST) GBP | RVI BIOTECNOLOGÍA | 86,826452 | 31/07/2026 | 10,03% | 11,33% | ** |
| JPM THEMATICS-GENETIC THERAPIES C (DIST) USD | RVI BIOTECNOLOGÍA | 62,751415 | 31/07/2026 | 10,20% | 11,53% | ** |
| JPM THEMATICS-GENETIC THERAPIES D (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 86,910000 | 31/07/2026 | 6,48% | 7,98% | ** |
| JPM THEMATICS-GENETIC THERAPIES D (ACC) USD | RVI BIOTECNOLOGÍA | 70,195908 | 31/07/2026 | 9,27% | 7,69% | ** |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 108,300000 | 31/07/2026 | 7,45% | 13,11% | ** |
| JPM THEMATICS-GENETIC THERAPIES I2 (ACC) USD | RVI BIOTECNOLOGÍA | 79,303439 | 31/07/2026 | 10,29% | 12,94% | ** |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR | RVI BIOTECNOLOGÍA | 77,780000 | 31/07/2026 | 10,20% | 13,00% | ** |
| JPM THEMATICS-GENETIC THERAPIES I (ACC) EUR (HEDGED) | RVI BIOTECNOLOGÍA | 76,130000 | 31/07/2026 | 7,39% | 12,79% | ** |
| JPM TOTAL EMERGING MARKETS INCOME A (ACC) EUR | MIXTO AGRESIVO GLOBAL | 150,790000 | 31/07/2026 | 12,64% | 36,71% | ***** |
| JPM TOTAL EMERGING MARKETS INCOME A (ACC) USD | MIXTO AGRESIVO GLOBAL | 150,439704 | 31/07/2026 | 12,65% | 36,28% | ***** |
